EDNRB and neoplasm: As a result, promotion of apoptosis via the ETB receptor is reduced or lost, suggesting the ETB receptor could be a target for epigenetic drugs or ETB agonists where ET may be the cause of some tumour types, including melanomas and oligodendrogliomas (Bagnato et al., 2011).